沙眼治療市場 - 按藥物類別、給藥途徑、年齡層、配銷通路、全球預測

Trachoma Treatment Market - By Drug Class, Route of Administration, Age-group, Distribution Channel, Global Forecast

出版日期: 2024年04月22日 | 出版商:

Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在四環素和阿奇黴素等治療藥物的進步以及政府的支持措施的推動下，全球沙眼治療市場從 2024 年到 2032 年將實現 5.9% 的複合年成長率。改良的藥物可以提高對抗引起沙眼的細菌感染的功效，而政府的資金和政策則可以促進獲得這些治療的機會。這些共同努力旨在減少全球沙眼的盛行率，強調透過提高該疾病仍然流行的地區的治療可及性和有效性來擴大市場。

例如，2023 年 12 月，英國皇家熱帶醫學與衛生學會與 Sightsavers 合作，在其期刊《國際健康》上發布了一份新的研究增刊，重點關注傳染性眼病沙眼的最新情況。這項進展顯示加強研究工作和更新治療策略，可能會改善診斷方法、治療介入和預防措施。它強調採取積極主動的方法來對抗沙眼，可能影響醫療保健政策、資金分配以及旨在減輕這種傳染性眼病全球負擔的國際舉措。

沙眼治療產業根據藥物類別、給藥途徑、年齡層、配銷通路和地區進行分類。

由於其在控制引起疾病的細菌感染方面的既定功效，四環素細分市場將在 2024 年至 2032 年間出現顯著的激增。包括阿奇黴素在內的四環素抗生素在治療和預防沙眼方面發揮關鍵作用，與全球衛生計劃保持一致。它們的有效性、易於管理和廣泛的可用性有助於它們在市場上的主導地位。隨著消除沙眼的努力不斷加強，四環素領域在提供具有成本效益和可擴展的治療解決方案方面的作用對於對抗全球範圍內這種導致失明的主要傳染性原因仍然至關重要。

由於其在分發四環素抗生素等藥物方面的可近性和便利性，到 2032 年，零售藥局將出現顯著的改善。由於這些藥物通常用於沙眼的治療和預防，因此零售藥局在確保廣泛供應方面發揮著至關重要的作用。他們廣泛的網路和以患者為中心的方法有效地滿足了對藥物解決方案的需求，為全球沙眼的管理和根除工作做出了重大貢獻。此細分市場的突出地位凸顯了其在促進這種可預防失明原因的基本治療方法方面的重要作用。

由於高盛行率和廣泛的政府舉措，亞太地區沙眼治療產業佔有率從 2024 年到 2032 年將實現適度的複合年成長率。該地區積極的醫療保健政策和不斷增加的公共衛生基礎設施投資有助於有效的疾病管理和治療的可近性。由於沙眼病例負擔沉重，特別是在農村地區，亞太地區作為沙眼治療市場的適度貢獻者，突顯了其致力於改善醫療保健結果和減少傳染性眼疾影響的承諾。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

AstraZeneca
Bausch Health Companies Inc.
Bayer AG
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Merck & Co., Inc.
Mylan N.V.
Novartis AG
Pfizer Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.

簡介目錄

Product Code: 9128

Global Trachoma Treatment Market will capture a 5.9% CAGR from 2024 to 2032, fueled by pharmaceutical advancements in treatments like tetracycline and azithromycin, coupled with supportive government initiatives. Improved medications enhance efficacy in combating the bacterial infection that causes trachoma, while government funding and policies bolster access to these treatments. These combined efforts aim to reduce the prevalence of trachoma globally, emphasizing the market's expansion through enhanced treatment accessibility and effectiveness in regions where the disease remains endemic.

For instance, in December 2023, the Royal Society of Tropical Medicine and Hygiene, in collaboration with Sightsavers, released a new research supplement in their journal International Health focusing on updates regarding the infectious eye disease trachoma. This development suggests heightened research efforts and updates on treatment strategies, potentially leading to improved diagnostic methods, therapeutic interventions, and preventive measures. It underscores a proactive approach towards combating trachoma, potentially influencing healthcare policies, funding allocations, and international initiatives aimed at reducing the global burden of this infectious eye disease.

The trachoma treatment industry is classified based on drug class, route of administration, age group, distribution channel, and region.

The tetracycline segment will observe a noteworthy surge between 2024 and 2032, driven by its established efficacy in managing the bacterial infection causing the disease. Tetracycline antibiotics, including azithromycin, are pivotal in treating and preventing trachoma, aligning with global health initiatives. Their effectiveness, ease of administration, and widespread availability contribute to their dominance in the market. As efforts to eliminate trachoma intensify, the tetracycline segment's role in providing cost-effective and scalable treatment solutions remains pivotal in combating this leading infectious cause of blindness worldwide.

The retail pharmacy will encounter a marked upturn through 2032 due to its accessibility and convenience in distributing medications like tetracycline antibiotics. As these medications are often prescribed for trachoma treatment and prevention, retail pharmacies play a crucial role in ensuring widespread availability. Their widespread network and patient-centric approach cater effectively to the demand for pharmaceutical solutions, contributing significantly to the management and eradication efforts against trachoma globally. This segment's prominence underscores its essential role in facilitating easy access to essential treatments for this preventable cause of blindness.

Asia Pacific trachoma treatment industry share will achieve a modest CAGR from 2024 to 2032, attributed to high prevalence rates and extensive government initiatives. The region's proactive healthcare policies and increasing investments in public health infrastructure contribute to effective disease management and treatment accessibility. With a significant burden of trachoma cases, particularly in rural areas, Asia Pacific's role as a modest contributor in the trachoma treatment market underscores its commitment to improving healthcare outcomes and reducing the impact of infectious eye diseases.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 High prevalence of trachoma particularly in developing regions
  - 3.2.1.2 Increasing government initiatives and funding
  - 3.2.1.3 Improved access to medicines
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Lack of awareness about trachoma
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Macrolides
5.3 Tetracycline
5.4 Ophthalmic anti-infective
5.5 Sulfonamides

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Oral
6.3 Topical

Chapter 7 Market Estimates and Forecast, By Age-group, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Children
7.3 Adults
7.4 Geriatric

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacy
8.3 Retail pharmacy
8.4 Online pharmacy

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa